NervGen Pharma Begins Trading on Nasdaq Today

Core Viewpoint - NervGen Pharma Corp. has received approval for its common shares to be listed on Nasdaq, marking a significant milestone in its development as a biopharmaceutical company focused on neuroreparative therapeutics for spinal cord injury and other neurological conditions [1] Company Overview - NervGen Pharma is a clinical-stage biopharmaceutical company developing first-in-class neuroreparative therapeutics aimed at transforming the lives of individuals with spinal cord injury (SCI) [2] - The lead therapeutic candidate, NVG-291, is a subcutaneously administered neuroreparative peptide that has shown durable improvements in function, independence, and quality of life in chronic SCI patients [2] - NVG-291 has received Fast Track designation from the FDA and Orphan Drug designation from the European Medicines Agency for the treatment of SCI [2] Recent Developments - The listing on Nasdaq is expected to enhance market visibility, improve liquidity, and broaden the shareholder base, ultimately driving long-term shareholder value as the company advances NVG-291 [1] - Recent Phase 1b/2a CONNECT SCI Study data revealed unprecedented durable improvements in function and quality of life for individuals with chronic SCI, with significant enhancements in upper-limb corticospinal signaling [1] - The company plans to conduct a U.S. FDA End-of-Phase 2 meeting in early 2026 to discuss the development and registration pathway for NVG-291 [1]